Health Economics›Malignant peritoneal mesothelioma›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Malignant peritoneal mesothelioma · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Atezolizumab and Bevacizumab Variant #01	—	R 59 878	21d	~11.2 mo	~19.2 mo	~17	~R 1 017 923 PFS proxy · indirect	2

1 of 1 regimen shown